Prognosis in UC After First Biological

Tampere University Hospital192 enrolled

Overview

To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.

UC patients treated with at least one biological in Tampere University Hospital between January 2009 and January 2020 were identified and reviewed from patient records.

Study Type

OBSERVATIONAL

Enrollment

192

Conditions

Ulcerative Colitis

Interventions

infliximab, adalimumab, golimumab, vedolizumab, ustekinumabBIOLOGICAL

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated for ulcerative colitis for the first trial of biological Exclusion Criteria: * Age under 16 years

Outcomes

Primary Outcomes

Response to treatment

Need for colectomy or enhancement of treatment within follow-up

Time frame: within 5 years

Side-effects

treatment related side-effects reported

Time frame: within 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.